Retatrutide Weight Loss: What Patients Need to Know

Moazma Ahmed

Medically reviewed by Moazma Ahmed, MPharm
UK-registered pharmacist and independent prescriber with specialist expertise in medical weight management and GLP-1 therapies.
Lead Prescriber at Live Well Weight Loss, responsible for clinical governance and content accuracy.

Last medically reviewed: 6th October 2026

This content is intended for UK patients and reflects MHRA and NICE guidance at the time of review.

Investigational weight loss treatment guide

Retatrutide UK: New Triple-Agonist Weight Loss Injection Explained

Retatrutide is an investigational once-weekly weight loss injection being developed by Eli Lilly. It has shown impressive clinical trial results, but it is not currently approved, prescribed, or legally available in the UK.

This guide explains what retatrutide is, how it works, the latest trial results, how it compares with Mounjaro and Wegovy, and why patients should avoid unregulated online sellers.

Check Approved Treatment Eligibility

Written by: Live Well Weight Loss Pharmacy Team

Clinically reviewed by: Moazma Ahmed, Pharmacist Independent Prescriber, GPhC 2069977

Last reviewed: June 2026

Next review due: September 2026

Quick Answer: Is Retatrutide Available in the UK?

No. Retatrutide is not currently approved by the MHRA and cannot be legally prescribed or supplied by UK pharmacies outside an authorised clinical trial. Any website, social media account, peptide seller, or private seller claiming to offer retatrutide in the UK should be treated as a serious safety risk. Products sold outside regulated clinical trials may be unlicensed, counterfeit, contaminated, incorrectly dosed, or stored incorrectly.

Important: Retatrutide is not a private prescription medicine in the UK. At present, patients should only use approved weight loss treatments prescribed through regulated healthcare services.

Retatrutide at a Glance

Question	Current answer
What is retatrutide?	An investigational once-weekly injection for obesity, type 2 diabetes, and related metabolic conditions.
Who makes it?	Eli Lilly.
How does it work?	It activates GLP-1, GIP, and glucagon receptors, so it is often described as a triple-agonist.
Is it approved in the UK?	No. It is not currently MHRA-approved.
Can UK pharmacies supply it?	No, not unless it becomes approved in the future.
Is it stronger than Mounjaro?	Trial results are very promising, but it is not yet approved and real-world use cannot be assessed yet.
Can I buy it online?	No legitimate UK provider can currently sell or prescribe retatrutide.

What Is Retatrutide?

Retatrutide, also known as LY3437943, is an investigational injectable medicine being studied for obesity, type 2 diabetes, and obesity-related health conditions. It is given once weekly in clinical trials. Retatrutide belongs to a newer group of medicines known as incretin-based therapies. These medicines act on hormone pathways that influence appetite, fullness, digestion, blood sugar regulation, and metabolism. The reason retatrutide has attracted so much interest is that it targets three receptor pathways rather than one or two. This triple action may help explain the high levels of average weight loss reported in clinical trials.

How Does Retatrutide Work?

Retatrutide activates three hormone receptors: GLP-1, GIP, and glucagon. Each pathway may contribute to weight loss and metabolic effects in a different way.

GLP-1

Helps reduce appetite, slow stomach emptying, increase fullness, and support blood sugar control.

GIP

Supports insulin response and may contribute to metabolic effects when combined with GLP-1 activity.

Glucagon

May increase energy expenditure and affect fat metabolism, but this pathway also needs careful safety monitoring.

In simple terms, retatrutide aims to reduce hunger while also influencing how the body uses energy. This is different from treatments that focus mainly on appetite suppression.

Retatrutide vs Mounjaro vs Wegovy

Patients often compare retatrutide with Mounjaro and Wegovy. The key difference is that Mounjaro and Wegovy are approved medicines, while retatrutide is still investigational.

Treatment	Active ingredient	Receptor activity	UK status
Wegovy	Semaglutide	GLP-1	Approved for weight management in suitable patients.
Mounjaro	Tirzepatide	GIP + GLP-1	Approved for weight management in suitable patients.
Retatrutide	Retatrutide	GIP + GLP-1 + glucagon	Investigational. Not currently approved or legally available in the UK.

It is too early to say where retatrutide will sit in routine clinical practice if it is approved. It may be considered for certain patient groups in the future, but this will depend on regulatory decisions, safety data, cost-effectiveness, and clinical guidance.

Latest Retatrutide Clinical Trial Results

Retatrutide has shown some of the largest average weight loss results reported in obesity medicine research so far. However, trial results do not mean the medicine is ready for routine use. Approval depends on full clinical trial data, regulatory review, safety evaluation, and future guidance.

Study	Population	Duration	Reported result
Phase 2 obesity trial	Adults with obesity	48 weeks	Mean weight loss reached up to 24.2% in the 12mg group, compared with 2.1% with placebo.
TRIUMPH-1 Phase 3 obesity trial	Adults with obesity or overweight	80 weeks	Lilly reported average weight loss of 70.3 lb, or 28.3%, with 12mg retatrutide.
Type 2 diabetes Phase 3 data	Adults with type 2 diabetes	40 weeks	Reported improvements in HbA1c and body weight compared with placebo.

These results are promising, but long-term safety, tolerability, cardiovascular outcomes, real-world prescribing, and UK access all remain important unanswered questions.

Retatrutide Side Effects and Safety

The most common side effects reported so far are similar to those seen with other incretin-based weight loss injections. These are mainly gastrointestinal and may be more noticeable when the dose is increased.

Reported common side effects

Nausea
Vomiting
Diarrhoea
Constipation
Reduced appetite
Abdominal discomfort

Safety areas being monitored

Heart rate
Blood pressure
Cardiovascular outcomes
Long-term tolerability
Gallbladder and pancreatic safety
Real-world treatment discontinuation

Because retatrutide also activates the glucagon receptor, researchers are paying close attention to metabolic and cardiovascular effects. This is one reason regulatory approval cannot be assumed from weight loss results alone.

Can You Buy Retatrutide Online in the UK?

No legitimate UK pharmacy or private clinic can currently supply retatrutide. If you see retatrutide advertised online, especially as a peptide, research chemical, or no-prescription injection, you should avoid it. Unregulated products may not contain the medicine claimed on the label. Even if they do, there is no assurance around dose accuracy, sterility, storage, cold-chain handling, expiry, contamination risk, or medical suitability.

Red flags for unsafe retatrutide sellers

Claims that retatrutide is available privately in the UK
No prescription or clinical assessment required
Sold as a “peptide”, “research product”, or “lab use only” product for personal use
Social media, WhatsApp, Telegram, or marketplace sellers
No UK pharmacy registration details
No prescriber details
No regulated cold-chain delivery process
Very low prices or bulk vial offers

When Could Retatrutide Be Available in the UK?

There is no confirmed UK approval date for retatrutide. Before it can be prescribed, the full clinical development programme must support its safety and effectiveness, and the medicine would need to go through regulatory review. If retatrutide is approved in the future, UK access would also depend on MHRA authorisation, prescribing guidance, commercial availability, and potentially NICE assessment for NHS use. Until then, patients should not try to source retatrutide from unofficial sellers. Approved options such as Mounjaro and Wegovy remain the clinically appropriate route for eligible patients seeking prescription weight loss treatment.

What Should Patients Do While Waiting for Retatrutide?

If you are interested in retatrutide because you have struggled with weight loss, the safest approach is to discuss approved treatment options with a regulated healthcare provider.

Mounjaro

An approved GIP and GLP-1 medicine used for weight management in suitable patients.

Wegovy

An approved GLP-1 medicine used for weight management in suitable patients.

Lifestyle support

Nutrition, physical activity, sleep, side effect management, and long-term maintenance planning all matter.

At Live Well Weight Loss, we only prescribe approved weight loss treatments after a clinical assessment. We do not supply investigational medicines such as retatrutide.

Check Eligibility for Approved Treatments

Is Retatrutide Available Through Live Well Weight Loss?

No. Retatrutide is not available through Live Well Weight Loss or any legitimate UK pharmacy because it is not currently approved for UK prescribing. We monitor developments in obesity medicine closely. If retatrutide is approved in the future and becomes clinically appropriate for UK patients, it would only be considered within a regulated prescribing framework with appropriate assessment, monitoring, and follow-up. In the meantime, we support eligible patients with approved treatments such as Mounjaro and Wegovy.

The Future of Medical Weight Loss

Retatrutide is part of a wider shift in obesity treatment. New medicines are being developed to target multiple hormonal pathways, with the aim of improving weight loss, metabolic health, and long-term maintenance. However, stronger weight loss results do not automatically mean a medicine is suitable for everyone. Future prescribing will need to balance effectiveness, safety, tolerability, cost, patient preference, and long-term outcomes.

Frequently Asked Questions About Retatrutide

Is retatrutide approved for weight loss in the UK?

No. Retatrutide is not currently approved by the MHRA and cannot be legally prescribed or supplied in the UK outside an authorised clinical trial.

Can I buy retatrutide privately?

No legitimate UK private clinic or pharmacy can currently prescribe or supply retatrutide.

How is retatrutide different from Mounjaro?

Mounjaro acts on GIP and GLP-1 receptors. Retatrutide acts on GIP, GLP-1, and glucagon receptors, making it a triple-agonist.

Is retatrutide better than Mounjaro?

Retatrutide has shown very high average weight loss in trials, but it is not yet approved. Mounjaro is already approved and has real-world prescribing experience.

What are the side effects of retatrutide?

Reported side effects include nausea, vomiting, diarrhoea, constipation, reduced appetite, and abdominal symptoms. Heart rate and cardiovascular effects are also being monitored in trials.

When will retatrutide be available in the UK?

There is no confirmed UK availability date. It would need regulatory approval and appropriate UK prescribing guidance before routine use.

Is retatrutide the same as a peptide?

Retatrutide is a medicine in clinical development. Products sold online as “retatrutide peptide” for personal use are not regulated UK medicines and should be avoided.

Will Live Well Weight Loss offer retatrutide in the future?

If retatrutide is approved in the UK and becomes clinically appropriate, we would review it in line with UK regulation, evidence, and prescribing guidance.

Looking for Approved Weight Loss Treatment?

Retatrutide is not currently available in the UK. If you want to explore approved options such as Mounjaro or Wegovy, complete an eligibility check and our clinical team will review your information.

Check Eligibility

Related Guides

References

Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine, 2023.
Eli Lilly and Company. TRIUMPH-1 Phase 3 obesity trial announcement, 2026.
ClinicalTrials.gov. Retatrutide obesity and overweight clinical trial programme.
MHRA. Warnings on unlicensed weight loss medicines and retatrutide products in the UK.
BNF and UK regulatory guidance for approved prescription weight loss medicines.